_____________
Snapshot overview: Partnership to enhance collaboration on rare diseases
_____________
Name: European Partnership on Rare Diseases
_____________
Institution/ DG/ Agency responsible at EU-level: European Innovation Council (Horizon Europe)
_____________
Work programme: Open-ended, yet to start
_____________
Programme: TBD
_____________
Programme budget: Overall budget of EUR 94.5 million, of which EUR 55 million is the Commission’s contribution. The remaining EUR 39.5 million corresponds to EUR 23.6 million of national in-cash contributions for the joint transnational calls and EUR 15.9 million of in-kind contributions to other activities foreseen in the programme (research & infrastructure building, training, support services).
_____________
Project budget: EUR 175 million of the proposed 7 years duration of the Partnership for Joint Transnational Calls (JTC); the funding of new or expanded networks established in the 7 years of the partnership is estimated to EUR 2.5 million; estimated budget to cover CRN research projects that will be funded through internal calls is of EUR 168 million.
_____________
Type of funding : The Partnership aims to implement an innovative and comprehensive approach to research funding and support including three major types of funding:
- Funding of transnational, collaborative and patient-needs driven research projects via open, competitive joint transnational calls involving national/regional research funding organisations
- Funding of networks (networking events/workshops) fostering building of new, or expansion of existing networks, with specific attention to sharing of knowledge and building connections between patients, researchers and clinicians around disregarded rare diseases
- Funding of “in house” collaborative and patient-needs driven research projects to be implemented under the strategic themes identified within the European Clinical Research Network for Rare Diseases
_____________
Target participants:
- National and regional research funders in the EU, Associated Members and Third Countries
- Universities, research organisations, and pan-European research infrastructures
- European Reference Networks
- Patient organisations
- Private foundations and philanthropy organisations
- There is a possibility for o the pharmaceutical, diagnostic and ICT sectors to explore co-sponsorship
_____________
Programme scope: Focus on rare diseases
_____________
Participant criteria: TBD
_____________
Project duration: Starting year: 2023/24 (7 years)
_____________
Average time from submission to project kick-off: TBD
_____________
R&D stage: TBD
_____________
Intellectual property: TBD
_____________
Project database: EU Funding & Tender Opportunities portal – Single Electronic Data Interchange Area (SEDIA)
_____________
Status: Expected to start in 2023/24. Currently being negotiated.
_____________
Contact details & more information:
